- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- September 2024
- 173 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- September 2024
- 175 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- March 2025
- 193 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- June 2024
- 183 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2018
- 450 Pages
Global
From €3326EUR$3,499USD£2,794GBP
- Report
- September 2023
- 80 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- January 2023
- 130 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- April 2023
- 41 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- January 2024
- 145 Pages
Global
From €4040EUR$4,250USD£3,394GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- November 2023
- 135 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- September 2023
- 179 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- January 2023
- 203 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- January 2023
- 85 Pages
Middle East, Africa
From €1426EUR$1,500USD£1,198GBP

The Inhalable market within the context of Respiratory Drugs is a rapidly growing sector of the pharmaceutical industry. Inhalable drugs are administered directly to the lungs, allowing for rapid absorption and a more targeted delivery of medication. This type of drug delivery is particularly useful for treating respiratory conditions such as asthma, COPD, and cystic fibrosis. Inhalable drugs are also used to treat acute conditions such as bronchitis and pneumonia.
Inhalable drugs are typically administered via a metered-dose inhaler (MDI) or a dry powder inhaler (DPI). MDIs are the most common type of inhaler, and they deliver a measured dose of medication in a pressurized aerosol form. DPIs are a newer type of inhaler, and they deliver a dry powder form of medication.
The Inhalable market is highly competitive, with many large pharmaceutical companies offering a variety of inhalable drugs. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Novartis, Merck, and Boehringer Ingelheim. Show Less Read more